Nabriva Therapeutics was founded in February 2006 as a spin-out of Sandoz GmbH. In early 2006, Nabriva raised Euro 42 Million in a Series A Financing Round from a group of top level international life science investors led by Nomura Phase4 Ventures. The Company’s current shareholders are Phase4 Ventures, HBM Partners, The Wellcome Trust, Global Life Science Ventures, Novartis Venture Fund and Sandoz GmbH. The same group of investors invested a further €15m in October 2009.